Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Thomas Locascio, BS | Image Credit: ENDO 2026

Recent data have shown that GLP-1 receptor agonist (RA) use is associated with a statistically significant increase in hypotension and related events among patients with preexisting 

Endocrine Society (ENDO) Annual Meeting 2026

 in Chicago, Illinois, by Thomas Locascio, BS, a gap year intern at Northwestern Medicine, reflect the widespread implementation and prescription of GLP-1s for 

, as well as their potential outside of endocrinology.

Due to their impact on cardiovascular, metabolic, and renal diseases, GLP-1s are prescribed for a long list of diseases across several conditions across the world. Despite this, data regarding their potential side effects are not complete. Gastrointestinal adverse events have been heavily studied since the drugs’ approval in the US – however, anecdotal evidence surrounding various adverse cardiovascular and renal outcomes continues to arise.

“GLP-1 RAs are widely prescribed to treat metabolic cardiovascular renal disease,” Locascio and colleagues wrote. “While most side effects are mild and related to the gastrointestinal system, anecdotal evidence of clinically significant hypotension has been reported.”

Locascio and colleagues structured the study around a within-person comparison, using a large-scale electronic health record database among outpatients prescribed GLP-1s including semaglutide, liraglutide, and tirzepatide. A total of 42,262 patients were included in the study, all of whom were aged ≥18 years and had taken ≥2 antihypertensive medication classes, as well as having document blood pressure measurements.

Patients were evaluated for hypotensive events in the 6, 12, and 24 months after treatment initiation – these events were defined as a combined endpoint of syncope or near-syncope, dizziness, falls, documented systolic blood pressure ≤90 mmHg, new diagnosis of hypotension, or anti-hypotensive drug prescription. Additionally, the team conducted a sub-analysis to examine the frequency of changes in antihypertensive therapy, such as reductions in the number of treatments and decreases in dosage. According to the investigators, these changes would reflect averted hypotension. The sub-analysis included 40 patients randomly selected from the 12-month post-initiation cohort.

Locascio and colleagues found that patients initiating GLP-1 RA treatment showed substantially higher rates of hypotensive events at all 3 timepoints. The incidence of hypotension rose from 8.7% at baseline to 10.2% at 6 months (

 <.001), from 13.6% to 14.3% at 12 months (

 = .003), and from 17.7% to 18.1% at 24 months (

 = .061). Hypotensive events were most frequent among patients aged ≥65 years, as well as those diagnosed with type 2 diabetes mellitus (T2DM). Antihypertensive medication dosage was reduced, or the number of prescribed medications was decreased, in roughly 25% of patients.

Locascio and colleagues ultimately concluded that GLP-1 RA usage is associated with a measurable and clinically significant increase in hypotensive-related events among patients with hypertension, increasing in frequency near the onset of treatment.

“Future analyses should investigate the role of weight loss in greater detail,” Locascio and colleagues wrote. “Findings from these studies can be used to identify who is at greatest risk so that interventions can be implemented to mitigate these complications.”

Eimer M, Chavez I, Locascio T. GLP1 Receptor Agonists and the Risk of Significant Hypotension Among Patients with Metabolic Cardiovascular Renal Disease: Too Much of A Good Thing? Abstract presented at the Endocrine Society (ENDO) Annual Meeting 2026, Chicago, IL. June 13-15.

Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021;12:721135. Published 2021 Aug 23. 

Articles

New real-world evidence suggests GLP-1 receptor agonist initiation modestly but significantly increases hypotension-related events in adults with established hypertension on at least two antihypertensive classes. Using a within-person EHR design, higher event rates were observed at 6 and 12 months, with attenuation by 24 months. Older adults and patients with type 2 diabetes had the greatest burden. Approximately one-quarter required antihypertensive dose reduction or de-escalation, implying clinically meaningful hemodynamic effects soon after therapy start. Further work is needed to clarify weight-loss mediation and risk stratification.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

GLP-1 Initiation Associated With Increase in Hypotensive Events in Patients With Hypertension

Hannah Rodriguez, MPAS, PA-C, is derm PA at Pennsylvania Dermatology Group.

How Environmental Triggers Impact Skin Disease, With Hannah Rodriguez, MPAS, PA-C

2026 Society of Dermatology Physician Assistants (SDPA)

 Summer Dermatology Conference, Hannah Rodriguez, MPAS, PA-C, highlighted the growing importance of understanding how environmental factors and climate change influence skin health and dermatologic disease.

 in an on-site interview, noting while the topic has not traditionally received significant attention at dermatology meetings, its relevance to patient care continues to expand as evidence accumulates linking environmental exposures to a range of skin conditions.

“I personally have always cared about the environment and our impact on the environment as humans,” Rodriguez noted. “As I started to realize what great impact the environment has on our skin patients, I felt really drawn to adopt this as a passion project.”

Rodriguez noted that her interest in the subject stems from both a personal commitment to environmental issues and mentorship from leaders in the field, including Misha Rosenbach, MD, at the University of Pennsylvania. She emphasized that clinicians must recognize that patients’ skin is constantly interacting with the environment, making it essential to understand how environmental changes can affect disease development, severity, and management.

According to Rodriguez, pollutants can impact the skin through multiple pathways. Airborne pollutants may directly contact the skin, contributing to barrier disruption and inflammatory responses, while pollutants that are inhaled or ingested can enter the bloodstream and subsequently affect the skin through systemic pathways. These exposures can alter immune function, disrupt the skin microbiome, impair barrier integrity, and increase inflammation.

She discussed how environmental factors can influence a variety of inflammatory skin diseases, including atopic dermatitis, acne, rosacea, and psoriasis. While the connection between environmental exposures and atopic dermatitis is relatively well established, Rodriguez suggested that many clinicians may be less aware of similar effects in other common dermatologic conditions. She also highlighted emerging evidence that rising temperatures can alter the skin microbiome and increase sebum production, potentially creating conditions that worsen acne severity.

Rodriguez encouraged clinicians to incorporate environmental considerations into patient counseling. One practical strategy is educating patients about the Air Quality Index (AQI), which can help them anticipate disease flares and adjust treatment plans proactively during periods of poor air quality. She also recommended the use of HEPA-filter air purifiers, particularly in bedrooms where individuals spend significant amounts of time.

Looking ahead, Rodriguez stressed that climate change may contribute to increased skin cancer risk through both greater cumulative sun exposure and intensifying ultraviolet radiation. As a result, she emphasized the continued importance of patient education regarding sunscreen use, sun-protective clothing, shade-seeking behaviors, and avoidance of peak sun exposure.

Disclosures: Rodriguez had no relevant disclosures of note.

Rodriguez H. Environmental/Geographic Influences in Dermatology Track: Under Pressure: Climate Change and the Future of Skin Health. Presented at SDPA Summer 2026. Jun 10-14, 2026.

Videos

This interview at the SDPA Summer Conference highlights the environment and climate change's impact on skin health and triggers of different conditions.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Real-world data evaluating the MiniMed™ 780G advanced hybrid closed-loop (AHCL) insulin pump system showed HbA1c decreased from 8.46% at baseline to 7.76% following initiation of the device (

 = .0018) in a cohort of 52 patients with diabetes.

Findings from the single-center retrospective analysis were presented at the 

in Chicago, Illinois, from June 13-16. Investigators reported a mean time in range (TIR) of 71.1%, exceeding the recommended target of ≥70%, alongside a mean time below 54 mg/dL of 0.08%, well below the <1% threshold for clinically significant hypoglycemia.

“The MiniMed 780G was associated with meaningful improvements in glycemic control while maintaining a low risk of severe hypoglycemia in routine clinical practice,” study investigator Sehrish Noorali, MD, a physician resident at St. Francis Emory Healthcare, and colleagues wrote.

The MiniMed 780G combines continuous glucose monitoring with automated insulin delivery technology designed to optimize glycemic control while reducing hypoglycemia risk.

The retrospective study evaluated 52 patients with diabetes who initiated the MiniMed 780G system. Participants had a mean baseline HbA1c of 8.46% (standard deviation [SD], 1.91%). Study investigators assessed glycemic outcomes using device-derived glucose management indicator (GMI), TIR, and time spent < 54 mg/dL, in addition to HbA1c values obtained from the electronic medical record.

Study investigators also stratified patients by use of manufacturer-recommended settings in a subgroup analysis. Of the study population, 28 patients were classified as using recommended settings (Rec+), and 17 were classified as using non-recommended settings (Rec−). In total, 7 patients with undocumented settings were excluded from subgroup analyses.

Subgroup analyses suggested adherence to recommended settings may enhance glycemic benefits. Patients in the Rec+ group experienced a greater reduction in HbA1c than those in the Rec− group (1.14% vs 0.49%). The reduction reached statistical significance in the Rec+ group (

 = .006) but not in the Rec− group (P = .055).

Investigators also observed significantly increased TIR among Rec+ patients compared with Rec− patients (75.5% vs 67.6%; 

 = .037). While mean GMI trended lower in the Rec+ group (6.99% vs 7.21%; 

 = .07), the difference did not reach statistical significance.

Based on these findings, investigators suggested that counseling patients on manufacturer-recommended settings at initiation may represent a practical strategy for maximizing the benefits of AHCL therapy.

Future analyses will examine whether use of the MiniMed 780G system is associated with reductions in hypoglycemia- or hyperglycemia-related emergency department visits and hospitalizations compared with multiple daily injection therapy or conventional insulin pump therapy without closed-loop automation.

Noorali S, Tandon R, Muldrow B, Serrano JT, Roboubiat A, Baliga BS. Glycemic outcomes with the MiniMed™ 780G advanced hybrid closed-loop system: real-world improvements in HbA1c, time in range, and hypoglycemia safety. Poster presented at: ENDO 2026: The Endocrine Society Annual Meeting; June 13, 2026; Chicago, IL. Poster SAT-875.

Bhargava A, Bergenstal RM, Warren ML, et al. Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes. 

Real-world retrospective data in 52 insulin-treated patients initiating the MiniMed 780G AHCL system demonstrated improved glycemic control with preserved hypoglycemia safety. Mean HbA1c decreased from 8.46% to 7.76% (P = .0018). Device-derived metrics showed mean time in range of 71.1%, meeting recommended thresholds, and time <54 mg/dL of 0.08%, indicating minimal clinically significant hypoglycemia. Subgroup analyses suggested manufacturer-recommended settings conferred greater HbA1c reduction and higher time in range than non-recommended settings.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Type 1 Diabetes

MiniMed 780G Associated With Reduced HbA1c, Increased Time in Range

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include new phase 3 data on survodutide in patients with obesity without type 2 diabetes, phase 2b results for elecoglipron in a pair of trials in obesity and type 2 diabetes, the first-ever cardiovascular-kidney-metabolic (CKM) syndrome guideline from the American Heart Association and the American College of Cardiology, the US Food and Drug Administration (FDA)’s addition of bemotrizinol as a permitted active ingredient in its list of over-the-counter sunscreen, and the Agency’s approval of a maintenance regimen of lebrikizumab (Ebglyss) 250 mg for moderate to severe atopic dermatitis.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of June 7, 2026 — let's jump in!

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D

Phase 3 data presented at the ADA Scientific Sessions 2026 in New Orleans, Louisiana, show survodutide, Boehringer Ingelheim’s investigative glucagon/GLP-1 receptor dual agonist, has demonstrated substantial weight loss and improved metabolic health in patients with obesity or overweight without type 2 diabetes. Carel le Roux, PhD, director of the Metabolic Medicine Group at the University College Dublin School of Medicine and a global coordinating investigator of the study, discussed the implications of these data for survodutide’s investigative future – as well as the patient population it aims to serve.

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data

AstraZeneca announced positive phase 2b results for elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), across a pair of trials in obesity and type 2 diabetes, paving the way for an extensive phase 3 program. Results from the VISTA and SOLSTICE trials were presented at the ADA 2026 Scientific Sessions in New Orleans and simultaneously published in 

In VISTA, adults with obesity or overweight receiving elecoglipron 75 mg achieved an average 10.5% reduction in body weight at 26 weeks versus 0.6% with placebo, with weight loss continuing to 11.8% at 36 weeks. In SOLSTICE, elecoglipron 75 mg reduced HbA1c by an average of 1.9% from baseline at 26 weeks versus 0.2% with placebo, with 90% of treated participants reaching an HbA1c below 7%.

AHA, ACC Issue First-Ever Clinical Guideline for Cardiovascular-Kidney-Metabolic Syndrome

The American Heart Association and the American College of Cardiology jointly issued the first-ever clinical guideline for cardiovascular-kidney-metabolic (CKM) syndrome, identifying excess weight, particularly in the abdomen, as a key driver for the syndrome's development and progress.

Recommendations include screening, prevention and treatment for people with or at risk of developing CKM syndrome. Healthy lifestyle behaviors; medications, including GLP-1-based therapies and SGLT2 inhibitors; and/or metabolic and bariatric surgery, when appropriate, are recommended with the goal of preventing, managing and potentially reversing CKM syndrome progression.

FDA Adds Bemotrizinol as First New Sunscreen Ingredient in Decades

On June 9, 2026, the FDA finalized an order including bemotrizinol as a permitted active ingredient in its list of over-the-counter (OTC) sunscreen products approved for skin cancer protection, marking the first addition of a new active ingredient to the OTC sunscreen monograph since the late 1990s.

According to the Agency, the ingredient has demonstrated low levels of systemic absorption through users’ skin and is considered generally recognized to be both safe and effective (GRASE) for implementation in sunscreen products in adults and children aged 6 months and older. The FDA's final order allows bemotrizinol at concentrations of up to 6%.

FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis

On June 9, 2026, the FDA approved a maintenance regimen of lebrikizumab (Ebglyss) 250 mg administered once every 8 weeks for adults and children aged 12 years and older weighing at least 40 kg with moderate to severe atopic dermatitis.

Lebrikizumab, an interleukin-13 (IL-13) inhibitor, received initial US approval in 2024 as a first-line biologic with once-monthly maintenance dosing and, more recently, long-term data have shown durable disease control with the agent through up to 4 years of continuous treatment.The every-8-week option reduces injection frequency for patients maintaining adequate clinical response.

Phase 3 ADA 2026 data indicate survodutide, a glucagon/GLP‑1 dual agonist, yields substantial weight loss with reductions in fat mass and hepatic steatosis in obesity without type 2 diabetes. Oral GLP‑1 RA elecoglipron delivered 10.5% weight loss at 26 weeks and 1.9% HbA1c reduction in phase 2b, supporting a phase 3 program. AHA/ACC released inaugural CKM syndrome guidance emphasizing abdominal adiposity and advocating lifestyle, GLP‑1/SGLT2 therapy, and bariatric surgery. FDA added bemotrizinol to the OTC sunscreen monograph and authorized 8‑week lebrikizumab maintenance dosing for atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 06/07

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has cleared Dexcom Inc.'s Stelo Glucose Biosensor System for over-the-counter (OTC) use in children as young as 2 years who do not use insulin, establishing the first OTC continuous glucose monitor (CGM) indicated for a pediatric population.

According to the FDA’s June 12, 2026 announcement, the expanded clearance extends the indication to individuals 2 years and older, including children with diabetes managed with oral medications and those seeking to understand how diet and exercise affect glucose levels.

"Children deserve access to the best tools available to manage their health," said Michelle Tarver, MD, PhD, Director of the FDA's Center for Devices and Radiological Health. "Today's clearance reflects the FDA's commitment to fostering innovation for pediatric patients and supporting the safe and effective use of medical devices where children live, learn, and play."

Stelo device design, sensor performance, and pediatric use considerations

The Stelo system consists of a wearable sensor paired with a compatible smartphone application, enabling continuous glucose measurement, recording, analysis, and display. The app updates glucose values every 15 minutes and supports use on a parent's or caregiver's device in addition to the child's own smartphone.

Each sensor is rated for up to 15 days of wear, though the FDA noted sensor wear time may run shorter in pediatric users than in adults due to interconnected physiological and behavioral factors. The device must be used under adult caregiver supervision for all pediatric patients.

The clearance relied in part on the FDA's use of real-world evidence (RWE), combining prior clinical study data from both pediatric and adult populations with real-world data on current integrated CGM (iCGM) use. This approach provided insight into expected device performance across the full 15-day wear period in younger users without requiring a dedicated pediatric trial.

Safety profile and contraindications for Stelo in children

In the prior clinical study referenced to support the clearance, participants reported mild adverse events including local infection, skin irritation, and pain or discomfort at the sensor site. The FDA noted no new safety signals were identified in the RWE analysis.

The system is not indicated for individuals with problematic hypoglycemia, as it does not issue low-glucose alerts. Stelo is also contraindicated for patients on dialysis. For patients with a personal history of disordered eating, consultation with a health care provider is recommended before use.

Health care providers should also be consulted before any medication adjustments are made based on the device's glucose output. The clearance aligns with the FDA's Home as a Health Care Hub Initiative, which advances patient-centered device development for use outside clinical settings.

The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to meals and activity, and support long-term health outcomes without a prescription barrier. 

FDA. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children. 

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children

. Published June 12, 2026. Accessed June 12, 2026.

Campbell P. FDA Clears Dexcom Stelo Sensor, First OTC Glucose Sensor in Agency History. Hcplive.com. Published March 5, 2024. Accessed June 12, 2026. 

https://www.hcplive.com/view/fda-clears-dexcom-stelo-sensor-first-otc-glucose-sensor-in-agency-history

The FDA cleared Dexcom’s Stelo Glucose Biosensor System for OTC use down to age 2 in individuals not using insulin, marking the first pediatric-indicated OTC CGM. Stelo pairs a wearable sensor with a smartphone app reporting glucose every 15 minutes and allowing caregiver monitoring. Clearance incorporated real-world evidence alongside prior adult and pediatric clinical data, avoiding a dedicated pediatric trial. Pediatric wear time may be shorter than 15 days and requires adult supervision. Stelo lacks hypoglycemia alerts and is contraindicated in dialysis.

The FDA has cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children as young as 2 years who do not use insulin.

FDA News

FDA Clears First OTC Glucose Monitor for Children

Teplizumab becomes the first disease-modifying therapy approved for patients recently diagnosed with stage 3 type 1 diabetes.

Teplizumab Receives Accelerated FDA Approval for Stage 3 T1D in Children

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

How to Approach Chronic Urticaria from Allergist and Dermatologist Perspectives

Manreet Kanwar, MD, is a professor of medicien and heart failure specialist at the University of Chicago Medicine.

Podcasts

HFA ESC 2026 highlights earlier advanced heart failure referral, LVAD vs transplant outcomes in seniors, and remote monitoring to catch decline sooner.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Heart Failure Congress 2026 Highlights, with Manreet Kanwar, MD

This SDPA interview with Steven Daveluy, MD, highlights integrative dermatology practices, acne strategies, and the value of supplements and dietary changes.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Can Supplements Help to Address Acne? With Steven Daveluy, MD

Octavio Galindo, MD, pediatric allergist from Clínica Universidad de Navarra.

Octavio Galindo, MD, discusses findings from a prospective Spanish cohort (SENDO) linking high UPF intake to asthma incidence in school-age children.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Ultra-Processed Food Consumption May Nearly Quadruple Childhood Asthma Risk

This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

How Can Oils, Acupressure, and Supplements Improve Skin Conditions?

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.

Closing Thoughts on ASCVD Management

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

ADA 2026 Recap: 5 Key Presentations to Know

In this SDPA Summer Dermatology Meeting interview, Zirwas speaks on treatment gaps for dermatologic conditions and off-label alternatives.

Key Off-Label Treatment Options in Dermatology, With Matthew Zirwas, MD

In this final episode, Dr. Cusano asks Dr. Dolores Shoback how she tailors communication for patients who are not meeting treatment goals, experiencing complications, or struggling with the burden of long-term disease management.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Latest News

GLP-1 Initiation Associated With Increase in Hypotensive Events in Patients With Hypertension

How Environmental Triggers Impact Skin Disease, With Hannah Rodriguez, MPAS, PA-C

MiniMed 780G Associated With Reduced HbA1c, Increased Time in Range

The HCPFive: Top News for Healthcare Providers from the Week of 06/07

FDA Clears First OTC Glucose Monitor for Children